Sign Up
Stories
Lilly's Missed Opportunity in Weight-Loss Drugs
Share
Amgen's Obesity Prospects and Q4 Results...
Biden's $35 Insulin Price Cap
Biopharma Innovations in Obesity and Mus...
Anti-Obesity Meds' Impact on Allurion Pr...
FDA Finds No Preliminary Link Between Oz...
FDA Warns of Counterfeit Ozempic
Overview
API
Eli Lilly missed a chance to enter the $80 billion weight-loss drug market, leading to a $600 billion industry. Richard DiMarchi discovered a gut hormone causing weight loss, filing a patent with a collaborator.
Ask a question
Could this incident serve as a cautionary tale for other companies in the healthcare sector?
How might Eli Lilly's missed opportunity impact the pharmaceutical industry's approach to obesity treatment?
What are the implications of this industry's growth for public health and healthcare systems?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage